CHF Solutions’ Physician-Led Webinar Highlights Real-World Evidence Supporting Effectiveness of Ultrafiltration in Heart Failure Patients

Rhea-AI Summary

CHF Solutions (Nasdaq: CHFS) has reported significant findings from a recent webinar discussing the ultrafiltration (UF) technique for managing heart failure. The retrospective study of 335 patients using the Aquadex FlexFlow® System showed favorable outcomes, including reduced rehospitalizations and improved renal function. Key observations indicated that Aquadex therapy can effectively decongest without harming renal health, allowing for reduced diuretic use post-treatment. The webinar highlighted early UF application's impact on patient outcomes and quality of life.

Positive

• Study of 335 patients shows UF with Aquadex FlexFlow reduces heart failure rehospitalizations.
• Reduced serum creatinine levels indicate improved renal function post-treatment.
• Patients discharged on 50% or less of previous diuretic regimens after using Aquadex.

Negative

• None.

EDEN PRAIRIE, Minn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced key takeaways from its physician-led webinar discussing real-world experience using ultrafiltration (UF) in the management of heart failure patients. Panelists discussed results from the real-world retrospective study of 335 consecutive patients treated with the Aquadex FlexFlow® System, published in Journal of Cardiac Failure Supplement, that demonstrated UF compares favorably in reducing heart failure rehospitalizations, renal function response, and weight/volume loss.

Important clinical observations from the study include:

• Quantifying the amount of fluid overload in a patient and whether they are adequately decongested can be difficult. It is important to understand the patient as a whole (i.e., medical history and weight at euvolemia stage).
• UF with Aquadex™ therapy adequately decongests patients without significant injury to the kidneys, as evidenced by reduced readmission rates, fluid loss, and serum creatinine levels reported in the study.
• When treating patients with advanced heart failure, it is important to know the cardiac output and cardiac index, and if the cardiac index is low, the panelists recommended support with inotropic therapy.
• When patients are not significantly intravascularly volume overloaded, but have evidence of congestion such as edema, using Aquadex at a low blood flow rate is an effective solution to permit plasma refill.
• Aquadex allowed for a resetting of the neurohormonal system and patients often were discharged on 50% or less of their previous diuretic regimen.
• Early application of ultrafiltration with Aquadex could improve patients’ outcomes sooner and quality of life (i.e., reduce hospital length of stay).

“Ultrafiltration continues to be an effective solution for heart failure patients as demonstrated by the decade of experience included in the study conducted by the phenomenal team at Abington-Jefferson,” said Nestor Jaramillo, Jr., President and CEO of CHF Solutions. “We appreciate the panelists sharing their extensive experience and thank them for their continued dedication to expanding industry knowledge on the benefits of effective fluid management.”

The webinar panelists included:

• Robert A. Watson III, MD, FAAC, Chief, Cardiology Division, Co-Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania
• Donald C. Haas, MD, Medical Director, Ventricular Assist Device Program; Co-Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania
• Maureen Hummel, CRNP, Clinical Director, Comprehensive Heart Failure Program at Abington Jefferson Health, Pennsylvania
• Patti Barrella, MSN, CHFN, Heart Failure Coordinator at Abington Jefferson Health, Pennsylvania
• John L. Jefferies, Jay M. Sullivan Distinguished Chair in Cardiovascular Medicine and Chief of Cardiology at the University of Tennessee Health Science Center
  

You can access the webinar replay on the CHF Solutions’ website and YouTube channel.

About CHF Solutions
CHF Solutions, Inc. (Nasdaq: CHFS) is a medical device company dedicated to improving the lives of patients suffering from fluid overload with its novel ultrafiltration therapy system. The company is focused on developing, manufacturing and commercializing the Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions is headquartered in Minneapolis, Minn., with wholly-owned subsidiaries in Australia and Ireland. The company has been listed on the Nasdaq Capital Market since February 2012.

About the Aquadex System
The Aquadex SmartFlow™ system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.

Forward-Looking Statements
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the use of Aquadex technology to treat heart failure patients. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. CHF Solutions does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

FAQ

What were the key findings from CHF Solutions' recent webinar regarding heart failure management?

The webinar highlighted that ultrafiltration using Aquadex FlexFlow significantly reduced rehospitalizations and improved renal function in heart failure patients.

How does Aquadex FlexFlow benefit heart failure patients according to the recent study?

The Aquadex FlexFlow system helps decongest patients without damaging kidney function, leading to lower readmission rates.

What was the sample size in the real-world study presented by CHF Solutions?

The study involved 335 consecutive patients treated with the Aquadex FlexFlow System.

When was the CHF Solutions webinar discussing ultrafiltration held?

The webinar took place on January 28, 2021.

What are the implications of the findings from CHF Solutions' webinar for heart failure treatment?

The findings suggest that early application of ultrafiltration may improve patient outcomes and reduce hospital stays.